Rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is a malignant mesenchymal neoplasm with skeletal-muscle differentiation, usually composed of primitive small round cells or spindle cells. The defining phenotype is myogenic rather than the presence of mature skeletal muscle at the site of origin: RMS most often arises in skeletal muscle but can develop in connective, adipose, or fibrous tissue, indicating that a tumor may originate where mature skeletal muscle is absent. ^[11] Nuclear expression of the myogenic transcription factors myogenin and MyoD1, together with desmin expression, supports the diagnosis, but interpretation requires correlation with morphology and exclusion of histologic mimics. ^[10]

The current histologic spectrum comprises five major diagnostic categories. These labels describe morphology and differentiation pattern; they do not, by themselves, determine biologic risk. ^[6]

A more clinically useful division cuts across morphology: RMS is either fusion-positive or fusion-negative. Fusion-positive disease is most often defined by a PAX3::FOXO1 or PAX7::FOXO1 rearrangement and is enriched in alveolar morphology, although morphology and genotype are not interchangeable. Fusion-negative RMS lacks these canonical FOXO1 fusions; pediatric fusion-negative tumors commonly carry RAS-pathway mutations, whereas MYOD1 and TP53 alterations are associated with adverse biology in selected tumors. ^[6] Thus, a report should state both the histologic category and fusion status rather than using “alveolar” as a surrogate for molecular risk. ^[6]

RMS is predominantly a disease of children and adolescents. It is the most common soft-tissue sarcoma in children, accounts for more than half of soft-tissue sarcomas in children and adolescents younger than 15 years, and becomes progressively less frequent with age. ^[6] Adolescents and young adults remain a clinically relevant group: the National Cancer Institute definition of this population includes patients aged 15-39 years, and RMS represents approximately 6.5% of soft-tissue sarcomas in this age range compared with approximately 2% in adults. ^[6] In adults, the distribution shifts toward pleomorphic and embryonal tumors, while alveolar RMS remains represented; adult series report pleomorphic RMS as the most frequent subtype. ^[6]

The diagnosis belongs within the differential diagnosis of pediatric small round cell tumors, but RMS is not synonymous with that morphologic pattern. Ewing sarcoma is a genetically defined round-cell sarcoma characterized most commonly by an EWSR1::FLI1 fusion, whereas desmoplastic small round cell tumor is defined by an EWSR1::WT1 fusion and typically presents as disseminated abdominopelvic disease. ^[6][16] Neuroblastoma , lymphoma , and malignant rhabdoid tumor can also enter the differential on limited tissue, but they represent distinct lineages and require different immunophenotypic and molecular confirmation; the diagnostic problem is greatest when a small biopsy is interpreted from morphology alone. ^[10][11] Other round-cell sarcomas, including CIC-rearranged sarcoma and EWSR1::PATZ1 sarcoma, may express overlapping markers or even be initially diagnosed as RMS, so a convincing myogenic phenotype should be integrated with molecular testing when morphology is atypical or the clinical context is discordant. ^[15][17]

Pearl: Diagnose RMS by demonstrating malignant skeletal-muscle differentiation, classify its histologic pattern, and report FOXO1 fusion status separately; the tumor’s site, age group, and microscopic architecture do not substitute for that integrated definition. ^[6][10]

RMS is uncommon overall but is predominantly a disease of childhood and adolescence; it is the most common soft-tissue sarcoma in this age range, whereas adult disease is distinctly less frequent ^[23]. Population-based surveillance of patients aged 0-39 years identified 2,676 primary RMS cases over 2000-2021, compared with 71 secondary cases, illustrating both the rarity of RMS and the small contribution of treatment-associated disease to the total burden ^[20]. The incidence peaks in early childhood, declines through later childhood, and shows a smaller second burden in adolescents and young adults; in adults, RMS is rare and is more often encountered as an unusual high-grade sarcoma than as a typical pediatric-pattern tumor. Age at presentation changes the prior probability of histologic subtype: embryonal tumors dominate childhood, alveolar tumors become relatively more prominent in older children and adolescents, spindle cell/sclerosing tumors span the pediatric-to-adult range, and pleomorphic tumors are concentrated in adults. Exact age-stratified percentages vary by registry, classification era, and whether fusion-defined categories are used, so percentages from selected pathology series should not be treated as population incidence estimates.

A modest male predominance is reported in several RMS cohorts, but it is not sufficiently strong to exclude RMS in girls or women. In a heterogeneous individual-patient analysis of spindle cell/sclerosing RMS, 55.9% of patients were male; this estimate is subtype-specific and cannot be applied to RMS as a whole ^[23]. Some molecularly defined tumors have a stronger sex bias: VGLL3-rearranged spindle cell rhabdomyoblastic tumors showed a male predominance and occurred exclusively in the head and neck in the reported series ^[1].

The distribution of histologic categories is therefore age-dependent rather than fixed. Embryonal RMS is the principal pediatric pattern and includes tumors arising in the genitourinary tract, head and neck, and other embryologically patterned sites. Alveolar RMS is particularly important in adolescents and young adults and is enriched in the extremities and trunk. Spindle cell/sclerosing RMS is uncommon but diagnostically relevant at every age; in a pooled series assembled largely from case reports, spindle cell tumors constituted 66.0%, sclerosing tumors 20.8%, and mixed spindle cell/sclerosing tumors 13.2%, figures that reflect referral and publication selection rather than true population proportions ^[23]. Pleomorphic RMS is predominantly an adult diagnosis. A tumor’s architecture should not be used as a substitute for molecular classification, because the clinical meaning of an alveolar pattern depends heavily on fusion status and spindle cell/sclerosing tumors contain biologically distinct molecular groups.

RMS can arise in almost any soft-tissue compartment because skeletal-muscle differentiation does not require a primary site containing mature skeletal muscle. Clinically, the most frequent anatomic groups are the head and neck, genitourinary tract, extremities, and trunk. Less common but high-consequence presentations involve the retroperitoneum and biliary tract. Biliary RMS is exceptionally uncommon, accounting for approximately 0.5% of pediatric RMS in one report, and often presents through biliary obstruction rather than a palpable mass ^[13]. Site influences the presenting symptom and the feasibility of local control: a head-and-neck tumor may present with obstruction, cranial-nerve dysfunction, or a visible mass; a genitourinary tumor with bleeding, urinary obstruction, or a polypoid lesion; an extremity or trunk tumor with an enlarging mass; and a retroperitoneal tumor with abdominal distension, pain, hydronephrosis, or vascular involvement. These patterns should guide imaging and biopsy planning but must not override the pathology-based diagnosis.

Inherited susceptibility

Most RMS is sporadic, and a germline predisposition should not be inferred from tumor histology alone. Consider genetic counseling and germline testing when RMS occurs at an unusually young age, when the patient has multiple primary tumors, when there is a strong or characteristic family history of early-onset cancer, when the tumor has a phenotype associated with a predisposition syndrome, or when tumor testing identifies a finding that may reflect constitutional disease. Counsel the family before testing, explain the possibility of an inherited result and implications for relatives, and use a germline multigene panel when the phenotype does not point reliably to one syndrome.

The most clinically consequential associations are summarized below. These associations alter surveillance for the patient, may affect local-treatment choices, and can identify at-risk relatives; they are not evidence that the RMS itself carries a germline alteration in every affected patient.

A germline result is particularly urgent in a child with RMS and a personal or family history suggestive of Li-Fraumeni syndrome, in a patient with pleomorphic RMS and mismatch-repair loss, and in a patient with cervical embryonal RMS or a DICER1-spectrum tumor. Tumor sequencing can provide the trigger for referral but cannot, by itself, distinguish a constitutional variant from a tumor-restricted alteration. The distinction matters for relatives, surveillance, reproductive counseling, and treatment decisions. For example, Li-Fraumeni syndrome markedly increases concern about radiation-induced malignancy, so local-control planning may favor surgery or other radiation-sparing strategies when oncologically acceptable ^[25]. In DICER1 syndrome, the diagnosis extends beyond the index RMS because the syndrome encompasses multiple benign and malignant tumors and supports risk-adapted surveillance for the patient and relatives ^[21].

Pearl: In RMS, age and site shape diagnostic suspicion, but a very young age, an unusual histologic subtype, multiple primaries, or a characteristic family history should trigger a genetics referral even when the tumor itself does not look syndromic.

Rhabdomyosarcoma (RMS) is best understood as a developmental malignancy in which a primitive mesenchymal cell acquires skeletal-muscle identity but fails to complete the differentiation program that would normally produce a mature, contractile myofiber. The proposed cells of origin include mesoderm-derived myogenic progenitors, cells related to satellite cells or other early skeletal-muscle precursors, and less-committed mesenchymal progenitors capable of being redirected toward myogenesis. This model explains why RMS can arise in sites that contain no mature skeletal muscle: the defining event is aberrant myogenic differentiation, not transformation of an existing muscle fiber. RMS cells commonly retain the myogenic regulatory factors MYOD1 and myogenin while remaining proliferative and developmentally immature, indicating that lineage specification and terminal differentiation have become uncoupled. ^[5][35]

The biology is therefore not simply “more muscle differentiation” or “less muscle differentiation.” Tumor cells activate part of the skeletal-muscle transcriptional program, which establishes the rhabdomyoblastic phenotype, but oncogenic transcriptional circuitry prevents the final withdrawal from the cell cycle. In fusion-driven alveolar RMS, the differentiation block is experimentally reversible: loss or pharmacologic inhibition of CDK8 impaired tumor growth and induced myogenic differentiation in vitro and in vivo. These findings support a mechanistic model in which malignant transformation preserves myogenic lineage while actively restraining its completion. ^[4][35]

Fusion-positive alveolar RMS

The defining lesions of fusion-positive alveolar RMS are reciprocal chromosomal rearrangements joining PAX3 or PAX7 to FOXO1 . PAX3 and PAX7 are developmental transcription factors that regulate progenitor-cell fate; FOXO1 is a transcriptional coactivator whose abnormal juxtaposition converts these partners into potent, dysregulated transcriptional drivers. The resulting fusion protein maintains an immature myogenic state and activates a gene-expression program that differs from normal muscle development. ^[4][33]

PAX3::FOXO1 is more common than PAX7::FOXO1, but both define the fusion-positive molecular class. Their presence explains why many tumors show alveolar architecture: cohesive tumor nests are separated by delicate septa, and central discohesion can create spaces resembling pulmonary alveoli. The architecture is a morphologic consequence of the tumor phenotype, not the molecular definition. A tumor with alveolar morphology but no FOXO1 rearrangement belongs to the fusion-negative group and should not be assigned the same biologic risk solely because it looks alveolar. ^[33]

FOXO1 fusion status carries greater prognostic information than alveolar morphology alone. Fusion-positive tumors generally represent a biologically aggressive class, whereas fusion-negative alveolar tumors are molecularly heterogeneous and may share the genomic features of embryonal or other fusion-negative RMS. This distinction matters because histologic appearance describes what the tumor looks like at one level of organization; molecular class describes the oncogenic program that sustains it. Single-cell studies also indicate that lethal RMS can converge on a shared high-risk cell state irrespective of fusion status, so FOXO1 status is a major classifier rather than an exhaustive explanation of clinical behavior. ^[33]

Fusion-negative and embryonal RMS

Fusion-negative RMS lacks a PAX3::FOXO1 or PAX7::FOXO1 driver and more often evolves through cooperation between developmental pathway disruption and proliferative signaling. Recurrent chromosomal gains involving chromosomes 2, 8, 12, and 13 and loss of heterozygosity at 11p15 are characteristic features of the embryonal molecular landscape. The 11p15 abnormality is biologically relevant because this region contains imprinted growth-regulatory domains, including the IGF2 locus; altered dosage can increase mitogenic signaling during a period when myogenic progenitors should be exiting the cell cycle. ^[5]

RAS-mitogen-activated protein kinase signaling is a recurrent route to transformation in fusion-negative RMS. Activating variants in NRAS , KRAS , and HRAS , or loss-of-function alterations affecting the negative regulator NF1 , increase signaling through RAS, RAF, MEK, and ERK. The consequence is persistent proliferation, survival, migration, and impaired differentiation rather than a new lineage identity. The same pathway can therefore appear in tumors with embryonal, spindle, sclerosing, or mixed morphology; morphology records the pattern of growth, whereas the RAS alteration identifies a signaling dependency. ^[5][8]

Additional alterations modify this background rather than define a single universal subtype. TP53 disruption removes a major checkpoint that normally eliminates cells with oncogenic or replication stress; CDKN2A loss weakens the p16-mediated brake on cyclin-dependent kinase activity; and MYCN gain or overexpression can reinforce proliferation and developmental immaturity. DICER1 , which encodes a central component of microRNA processing, is particularly relevant to a subset of embryonal RMS, including cervical tumors, because altered microRNA maturation can distort developmental gene regulation. FGFR4 abnormalities or increased FGFR4 signaling may provide an additional growth and survival signal in RMS, but FGFR4 alteration does not by itself define the diagnosis. ^[7][21][36]

The combination of these lesions is more informative than any isolated mutation. A fusion-negative tumor with a RAS-pathway alteration may retain a relatively recognizable embryonal program, whereas acquisition of TP53, CDKN2A, or other cell-cycle abnormalities can produce a more pleomorphic or clinically aggressive phenotype. Conversely, the presence of a mutation should not be used as a substitute for integrated morphologic and immunophenotypic diagnosis, because similar alterations may occur in related developmental tumors or in sarcomas with aberrant myogenic differentiation. ^[3][5][38]

MYOD1-mutant spindle cell and sclerosing RMS

Spindle cell/sclerosing RMS is a morphologic category, not a single molecular disease. Some tumors are driven by alterations involving MYOD1 , the master myogenic transcription factor; others harbor RAS-pathway abnormalities, gene fusions such as VGLL3 rearrangements, or changes that remain incompletely characterized. The spindle-cell or sclerosing appearance therefore cannot predict the underlying driver without molecular classification. ^[5][33]

The recurrent MYOD1 p.L122R mutation is biologically distinctive because it alters the function of a protein that normally commits progenitors to skeletal-muscle differentiation. Rather than merely activating proliferation, the mutant transcription factor can impose an abnormal myogenic program while maintaining malignant self-renewal. This explains the characteristic combination of spindle or sclerosing morphology, myogenic marker expression, and aggressive behavior in MYOD1-mutant RMS. The tumor is still “myogenic,” but its differentiation program has been rewired into a malignant state. ^[36]

This example illustrates the essential distinction between molecular class and histologic appearance. “Spindle cell RMS” describes cellular shape and stromal pattern; “MYOD1-mutant RMS” describes a pathogenic transcriptional alteration. Two spindle-cell tumors may therefore have different biology, prognosis, and genomic relationships, while a molecularly related group may show spindle, sclerosing, or less typical morphology. Classification should preserve both descriptors: morphology communicates the tissue pattern, and molecular findings identify the biologic class. ^[33]

The central pathogenetic principle is that RMS arises when a myogenic or mesenchymal progenitor is trapped between lineage commitment and terminal differentiation. Fusion proteins, RAS-pathway activation, MYOD1 mutation, altered cell-cycle checkpoints, copy-number imbalance, and disrupted microRNA processing reach that state through different routes. The resulting tumors may look alike under the microscope or look different despite sharing a driver; molecular classification is therefore necessary to explain the heterogeneity that morphology alone cannot resolve. ^[4][5][33]

The presenting syndrome of rhabdomyosarcoma is determined chiefly by anatomy. A rapidly enlarging, usually painless mass is the commonest clue, but pain, impaired movement, compression of adjacent organs, or neurologic deficit may dominate when the tumor occupies a confined compartment. RMS can arise in any anatomic site, and its clinical manifestations therefore range from a visible superficial lesion to occult deep disease with obstruction or cranial-nerve dysfunction.^[41]

A superficial mass is often firm, enlarging, and painless; tenderness may develop from hemorrhage, rapid expansion, inflammation, or pressure on nerves. A deep soft-tissue tumor may be difficult to palpate and may first cause loss of function, restricted joint movement, gait change, venous or lymphatic edema, or neuropathic pain. Examine the mass for size, depth, fixation, skin change, temperature, and transillumination where relevant; document motor, sensory, and distal vascular function. Do not dismiss a small or apparently benign mass if it enlarges, recurs after excision, or produces progressive functional impairment. The trunk and extremity subgroup is clinically consequential because metastasis at diagnosis and macroscopic residual disease were associated with relapse or progression in a retrospective pediatric cohort.^[32]

Head-and-neck disease requires anatomic localization rather than reliance on the external examination. Orbital RMS typically produces unilateral eyelid swelling, proptosis, globe displacement, diplopia, or visual symptoms; an apparently inflammatory orbital swelling that progresses over days to weeks warrants urgent orbital imaging. Orbital disease is often localized at presentation, but relapse is predominantly local, so assess visual acuity, pupils, ocular motility, optic-nerve function, and fundus findings.^[42] The parameningeal group includes nasal, nasopharyngeal, paranasal, middle-ear, infratemporal, and skull-base sites. Nasal or nasopharyngeal tumors may cause persistent unilateral obstruction, epistaxis, discharge, facial swelling, headache, or conductive hearing loss; extension toward the skull base may produce facial numbness, diplopia, dysphagia, or other cranial-nerve deficits. MRI of the face, skull base, and brain should define intracranial, meningeal, orbital, perineural, and vascular relationships before biopsy or other local intervention. Parameningeal tumors have a particular propensity for local progression; in one retrospective cohort, local recurrence or progression accounted for most relapses, and parameningeal location was associated with worse survival than orbital disease.^[42]

Middle-ear or temporal-bone RMS can mimic chronic otitis media. Persistent otorrhea, otalgia, hearing loss, an aural polyp, or failure to respond to appropriate treatment should prompt imaging rather than repeated empiric treatment. Facial-nerve palsy is an especially concerning sign of temporal-bone or skull-base involvement. A systematic review of 68 pediatric cases found persistent otorrhea in 73%, otalgia in 42%, and facial-nerve palsy in 69%; imaging commonly showed an osteolytic middle-ear or mastoid mass with skull-base or intracranial extension.^[43] Obtain contrast-enhanced MRI of the temporal bones and skull base, supplemented by CT when bony destruction must be characterized.

Genitourinary and gynecologic RMS often presents through obstruction, bleeding, or a mass visible at a mucosal orifice. Bladder tumors may cause frequency, dysuria, hematuria, urinary retention, or hydronephrosis; prostatic tumors may cause poor stream, constipation from pelvic compression, urinary retention, or a palpable pelvic mass. A normal prostate-specific antigen does not exclude prostatic RMS, which can resemble poorly differentiated carcinoma clinically and radiologically.^[51] Paratesticular disease usually appears as a painless, enlarging scrotal or paratesticular mass; examine the testes, epididymides, spermatic cords, inguinal canals, and regional nodes, and use scrotal and inguinal ultrasonography to establish whether the lesion is intratesticular or paratesticular. Intratesticular RMS is rare and may progress with recurrence or distant metastasis, so an apparently solid testicular mass requires prompt oncologic evaluation rather than observation.^[50]

Vulvovaginal RMS may present as a painless polypoid mass, vaginal bleeding, discharge, pain, or a mass protruding through the introitus. Uterine disease may cause abnormal uterine bleeding, pelvic pain, or an enlarging pelvic mass. Inspect the vulva and introitus when symptoms permit, avoid traumatic manipulation of a friable protruding lesion, and obtain pelvic MRI to define vaginal, cervical, uterine, bladder, rectal, and parametrial extension. In a pediatric cohort, primary tumors included vaginal and bladder sites among tumors that achieved complete response after systemic treatment, illustrating that these lesions may be clinically apparent yet anatomically difficult to assess by examination alone.^[41]

Retroperitoneal RMS is characteristically insidious because the tumor can enlarge within a compliant deep compartment before producing local symptoms. Abdominal pain and a palpable abdominal mass are common clues; abdominal distension, vomiting, dyspnea, limb or scrotal edema, hydronephrosis, and renal dysfunction indicate mass effect or invasion. In a retrospective series of 17 children, abdominal pain and a palpable mass each occurred in six patients, while vomiting with distension, dyspnea, scrotal edema, and lower-extremity edema were also reported; hydronephrosis was detected in 6 of 16 evaluable patients.^[28] Perform a complete abdominal, pelvic, neurologic, and vascular examination and obtain contrast-enhanced CT or MRI of the abdomen and pelvis. Imaging must identify the organ of origin, ureteral obstruction, renal and bowel involvement, and encasement or invasion of the aorta, iliac vessels, mesenteric vessels, and renal vessels; deep location and nonspecific symptoms make initial misdiagnosis common.^[28]

Biliary-tract RMS is exceptionally uncommon but has a recognizable obstructive presentation: progressive jaundice, dark urine, pale stools, pruritus, abdominal pain, fever from cholangitis, or cholestatic laboratory abnormalities. A hilar mass may be mistaken for a choledochal cyst or other benign biliary lesion. Ultrasound followed by contrast-enhanced CT or MRI with magnetic resonance cholangiopancreatography should define the mass and the level of ductal obstruction; urgent assessment is required when cholangitis or worsening hepatic dysfunction is present. A reported child with biliary RMS had obstructive jaundice and a solid hilar mass with biliary dilation on multimodality imaging.^[13]

Metastatic disease may be clinically silent, so a normal examination and absence of respiratory, skeletal, or constitutional symptoms do not exclude it. Pulmonary metastases may cause cough, tachypnea, pleuritic pain, or dyspnea, but are often detected only on chest imaging. Osseous metastases may cause focal bone pain, limp, pathologic fracture, or spinal symptoms; vertebral disease requires urgent assessment for cord compression. Bone-marrow involvement may produce pallor, fatigue, bruising, recurrent infection, or cytopenias, although marrow-confined RMS can mimic leukemia and present without an identifiable soft-tissue mass.^[11] Distant nodal disease may manifest as a palpable cervical, supraclavicular, axillary, or inguinal node, abdominal mass, edema, or organ-specific compression, but may also be radiographic only. In a pediatric cohort with metastatic RMS, bone and lung were the most frequent metastatic sites, while a retroperitoneal series also documented distant lymph nodes, pleura, peritoneum, brain, and other sites.^[41][28] Evaluate suspected dissemination with symptom-directed examination and appropriate cross-sectional imaging; include chest imaging and assess bone and marrow when clinical findings or imaging raise concern.

Pearl: An enlarging painless mass, persistent site-specific obstruction or bleeding, an unexplained cranial-nerve deficit, or an “infection” that fails to resolve should trigger imaging and tissue diagnosis; a lack of symptoms does not make metastatic RMS unlikely enough to omit systemic evaluation.^[28][43]

Begin with a coordinated clinical assessment rather than an isolated scan. Document the tempo of growth, pain, bleeding, obstruction, fever, weight change, respiratory symptoms, and neurologic complaints; ask about prior malignancy or radiotherapy, relevant cancer-predisposition features, medications, allergies, and pregnancy possibility in patients who could be pregnant. Examine the mass for size, depth, fixation, skin involvement, tenderness, and relation to the neurovascular bundle, then record motor and sensory function and distal perfusion. Examine regional nodal basins and the likely routes of local extension: cranial nerves and vision for orbital or parameningeal tumors, hearing and the facial nerve for temporal-bone disease, pelvic and perineal structures for genitourinary tumors, and abdominal organs, bowel, ureters, and vascular status for retroperitoneal or biliary disease. Persistent otorrhea, hearing loss, an aural polyp, or facial palsy warrants prompt imaging rather than prolonged treatment for otitis media ^[43].

Obtain a complete blood count with differential and platelet count, comprehensive chemistry profile, liver tests, bilirubin, albumin, coagulation studies when intervention is planned, and urinalysis. Establish renal function before iodinated contrast, anesthesia, or nephrotoxic therapy; assess hepatic function before drugs requiring hepatic metabolism or dose adjustment; and obtain an electrocardiogram and echocardiogram when anthracycline exposure is anticipated or cardiac disease is suspected. Perform pregnancy testing before ionizing radiation, sedation, or cytotoxic treatment when pregnancy is biologically possible. These tests establish treatment fitness, identify cytopenias or organ dysfunction that may reflect advanced disease or alter therapy, and provide baseline values for subsequent toxicity monitoring. Obstructive biliary tumors require particular attention to conjugated bilirubin and hepatic indices because biliary rhabdomyosarcoma commonly presents with direct hyperbilirubinemia and elevated liver enzymes ^[13].

Imaging strategy

Use contrast-enhanced MRI as the preferred local study for most extremity, trunk, head-and-neck, pelvic, and genitourinary tumors. MRI defines the three-dimensional tumor extent, depth, relationship to muscle, fascia, bone marrow, vessels, nerves, orbit, skull base, pelvic organs, and mucosal surfaces; include diffusion-weighted sequences when feasible. For parameningeal disease or neurologic symptoms, extend MRI to the skull base and brain, and image the spine when there is back pain, weakness, sensory change, sphincter dysfunction, or concern for epidural or leptomeningeal spread. MRI is the modality of choice for local staging because it delineates the primary tumor and its relationship to adjacent structures, including possible perineural or bone-marrow involvement ^[55].

Use CT when MRI is contraindicated, unavailable, poorly tolerated, or technically inadequate. CT is also the practical complementary study for the chest, cortical bone destruction, calcification, acute mass effect, and thoracic or abdominal anatomy. Obtain thin-section contrast-enhanced chest CT for pulmonary metastases; do not substitute 18F-FDG PET/CT for dedicated chest CT when small lung nodules would change management, because subcentimeter pulmonary lesions may be missed on PET/CT ^[55].

Stage the whole patient, not merely the primary site. Chest CT is routine because the lung is a frequent metastatic compartment. Add PET/CT or whole-body MRI when metastatic disease is suspected, conventional studies are discordant, nodal or osseous disease would alter risk assignment, or a single examination could reasonably consolidate systemic staging. PET/CT is an adjunct rather than an automatic replacement for conventional imaging: its role in rhabdomyosarcoma continues to evolve, and no randomized trial has shown that PET-guided staging improves survival ^[55]. PET/CT also does not reliably exclude low-volume or diffusely infiltrative marrow disease; perform marrow aspiration and biopsy when cytopenias, diffuse marrow abnormalities, or protocol-defined risk assessment warrant tissue confirmation ^[55].

Use targeted studies for the anatomy suggested by symptoms and the primary site. Ultrasound is useful for a superficial mass, scrotal or inguinal disease, and initial assessment of biliary obstruction, but a solid vascular hilar mass with ductal dilatation requires cross-sectional imaging; biliary MRI should include magnetic resonance cholangiopancreatography when ductal anatomy is central to the question ^[13]. CT is particularly useful for temporal-bone cortical destruction, while MRI evaluates skull-base and intracranial extension ^[43].

Biopsy planning

Obtain tissue before definitive treatment unless an immediately life-threatening complication requires urgent intervention. Image-guided core-needle biopsy is the usual approach for an accessible soft-tissue mass because it provides tissue while limiting disruption of uninvolved planes. Plan the biopsy at a multidisciplinary conference with radiology, pediatric or medical oncology, surgery, radiation oncology, anesthesia, and pathology. The needle track, incision, and any drain path must lie within the compartment that can later be removed en bloc with the definitive operation; for a limb or trunk lesion, avoid crossing uninvolved compartments, neurovascular structures, or joint spaces. Do not perform an unplanned excision of a presumed benign mass and do not biopsy through an avoidable compartment. The biopsy approach matters because later local therapy depends on the contaminated tissue plane, and diagnostic errors from inadequate sampling can redirect systemic treatment ^[14].

Target the enhancing, solid, viable component rather than necrotic or hemorrhagic regions, and obtain several cores when safely possible. Send fresh or appropriately handled material according to local pathology requirements so that morphology, immunohistochemistry, and molecular testing can be completed; do not exhaust the specimen on ancillary studies before confirming that adequate tissue remains for the integrated diagnosis. A discordant clinical, radiologic, and preliminary pathologic impression warrants review by a sarcoma pathologist and additional sampling rather than empiric treatment based on a small or nonrepresentative fragment ^[14].

Use an incisional biopsy when a core biopsy cannot safely provide adequate viable tissue, when the lesion is superficial and an open approach can be placed directly in the eventual resection field, or when anatomy makes image-guided cores unreliable. Orbital tumors are a specific example in which current recommendations favor an open incisional procedure, while contemporary orbital series support biopsy-only management rather than debulking as the diagnostic operation ^[57][56]. For biliary or other anatomically constrained tumors, endoscopic or open biopsy may be required after imaging has defined a safe route; a reported hilar biliary tumor required open biopsy after multimodality imaging and biliary decompression ^[13].

Record the biopsy site, number and gauge of cores, imaging target, complications, and the planned surgical pathway in the clinical note. Present the case at a specialized multidisciplinary meeting before biopsy whenever feasible; higher-volume centers show greater adherence to central pathology review and molecular testing, and risk-group misclassification remains a measurable consequence of variable diagnostic processes ^[27].

Pearl: In rhabdomyosarcoma, the safest biopsy is not simply the one that yields tissue; it is the one that yields representative tissue without compromising the compartment through which definitive local treatment must proceed.

Examine the specimen fresh, orient it, measure the tumor in three dimensions, and describe its relationship to the biopsy tract, fascia, neurovascular structures, and any adjacent organ. On cut section, record whether the lesion is solid, cystic, hemorrhagic, or necrotic; spindle cell/sclerosing tumors may be nodular or multinodular with gray-white to yellow surfaces and variable cystic change. ^[23] Submit tissue from viable, heterogeneous areas because necrosis and hemorrhage can obscure the primitive component and compromise molecular testing. ^[23]

Microscopically, assess the tumor at low power before focusing on cytologic detail. The classic botryoid or mucosal form shows a dense subepithelial condensation of tumor beneath the epithelium, the cambium layer, overlying a more loosely cellular tumor. This pattern supports embryonal RMS but is not, by itself, sufficient for diagnosis. Elsewhere, RMS may be composed of primitive round cells in sheets, nests, or loose aggregates; cells can have scant cytoplasm and hyperchromatic nuclei, or more abundant eosinophilic cytoplasm when rhabdomyoblastic differentiation is present. Search deliberately for rhabdomyoblasts, cross-striations, and strap, tadpole, or racquet-shaped cells, but do not require them: overt skeletal-muscle morphology is often focal or absent. Spindle cell and sclerosing areas may resemble myofibroblastic or smooth-muscle neoplasms; sclerosing areas contain hyalinized, densely collagenous stroma, whereas spindle cells form fascicles, storiform arrays, or haphazard infiltrates. ^[23]

Alveolar architecture consists of nests of discohesive cells separated by delicate fibrovascular septa, sometimes with central cellular loss that produces an alveolar appearance. Solid areas are common, particularly in small biopsies, so “alveolar” morphology should trigger fusion testing rather than substitute for it. Pleomorphic RMS contains markedly atypical, bizarre, or multinucleated cells admixed with recognizable rhabdomyoblastic differentiation; exclude an undifferentiated pleomorphic sarcoma or a sarcomatoid carcinoma before assigning this diagnosis. The degree of pleomorphism, mitotic activity, or necrosis should be reported descriptively, not used as a surrogate for molecular classification. ^[3]

Use immunohistochemistry as a lineage-confirmation panel, not as an isolated positive stain. Desmin is a sensitive cytoplasmic muscle marker, while nuclear myogenin and MyoD1 provide stronger evidence of skeletal-muscle differentiation when staining is present in tumor cells rather than entrapped myocytes. Myogenin may be focal in poorly differentiated or spindle-cell tumors; MyoD1 can be more extensive in these lesions. In a pooled spindle cell/sclerosing series, desmin, MyoD1, and myogenin were the most frequently positive muscle markers, but the denominators varied because not every case underwent every stain. ^[23] MYF4 and muscle-specific actin or SMA may support myogenic differentiation, although SMA is less specific and can be focal. ^[23]

Interpret staining in its morphologic context. Desmin, myogenin, and MyoD1 do not establish RMS when staining is limited to entrapped skeletal muscle, and aberrant expression of keratins, CD99, SMA, or S100 can mislead. Adult sinonasal RMS was initially interpreted as neuroendocrine carcinoma until strong nuclear MyoD1 and myogenin, together with negative epithelial and neuroendocrine markers, resolved the diagnosis. ^[10] Conversely, a negative or weak marker does not exclude RMS in a small, necrotic, decalcified, or poorly differentiated sample. Repeat stains on better tissue and obtain expert review when morphology, immunophenotype, and clinical setting disagree.

The differential diagnosis should be resolved with a deliberately chosen panel. Ewing sarcoma is usually supported by diffuse membranous CD99 and an appropriate EWSR1 -ETS fusion, whereas RMS requires convincing nuclear myogenic differentiation and, when indicated, FOXO1 fusion testing. Lymphoma is assessed with leukocyte markers such as CD45 and lineage-specific B- or T-cell markers. Neuroblastoma is favored by neuropil and neuroendocrine markers such as synaptophysin and chromogranin , while a poorly differentiated carcinoma requires epithelial markers including broad-spectrum cytokeratin and EMA . In a prostatic small round-cell tumor, skeletal-muscle markers combined with negative keratin, NKX3.1, synaptophysin, and chromogranin redirected the diagnosis from carcinoma to alveolar RMS. ^[51] Consider desmin , myogenin, and MyoD1-positive melanoma with rhabdomyoblastic transdifferentiation when there is a history of melanoma; such tumors can lose all conventional melanocytic markers, and sequencing may be required to reveal a melanoma-type genomic signature. ^[38]

Do not diagnose primary RMS in a retroperitoneal mass solely because the tumor expresses myogenic markers. Dedifferentiated liposarcoma with heterologous rhabdomyoblastic differentiation may express desmin, myogenin, and MyoD1; amplification testing for MDM2 and CDK4 can expose the underlying liposarcoma. ^[40] In a head-and-neck or sinonasal spindle-cell lesion, consider biphenotypic sinonasal sarcoma, including high-grade rhabdomyosarcomatous transformation, and test for a PAX3 rearrangement or fusion when morphology and site support it. ^[19] In a thoracic mass of an infant or young child, especially with cystic change, pneumothorax, or marked mass effect, retain pleuropulmonary blastoma in the differential; limited biopsy has led to an erroneous diagnosis of embryonal RMS, and expert review with DICER1 testing may correct it. ^[14]

Molecular classification

Test for a FOXO1 rearrangement or a PAX3 :: FOXO1 or PAX7 :: FOXO1 fusion when alveolar architecture is present, when a primitive round-cell tumor has convincing skeletal-muscle differentiation, or when the diagnosis is otherwise difficult. An RNA-based assay is preferable because it identifies the expressed fusion transcript and its partner; validated alternatives include reverse-transcription polymerase chain reaction, fluorescence in situ hybridization, or another validated equivalent method. RNA sequencing can detect known and novel fusion partners through anchored multiplex polymerase-chain-reaction approaches. ^[19] A break-apart FISH result establishes rearrangement of the tested locus but may not identify the partner; a negative result on scant or degraded tissue should prompt review of assay adequacy and consideration of RNA sequencing rather than automatic classification as fusion-negative.

Report RMS in two dimensions: histologic pattern and molecular class. Alveolar architecture without a FOXO1 rearrangement is not equivalent to fusion-positive alveolar RMS, and spindle or sclerosing morphology encompasses genetically distinct tumors. MYOD1 p.L122R is particularly relevant in spindle/sclerosing RMS because recurrent MYOD1 mutations, often with PIK3CA alterations, define a clinically aggressive subset in published series. ^[23] By contrast, VGLL3-rearranged spindle cell rhabdomyoblastic tumors show fascicular or storiform spindle-cell growth, absent necrosis, low mitotic activity, diffuse desmin, and variable MyoD1 or myogenin; reported fusions include EP300::VGLL3, TCF12::VGLL3, and PPARGC1A::VGLL3. ^[1] These findings justify molecular testing in an apparently bland spindle-cell tumor with skeletal-muscle differentiation rather than assuming conventional embryonal RMS.

Use targeted sequencing selectively but proactively. Test MYOD1 in spindle cell/sclerosing tumors, especially those with marked atypia or an aggressive clinical course; test TP53 when pleomorphism, high-grade morphology, or a possible hereditary cancer syndrome raises concern; and assess RAS-pathway genes, including NRAS , KRAS , and HRAS , in fusion-negative tumors or diagnostically unresolved embryonal, spindle, and sclerosing lesions. Consider DICER1 testing in cervical embryonal RMS, in a patient with a phenotype or tumor history suggestive of DICER1 syndrome, and in unusual thoracic or pediatric tumors that overlap with pleuropulmonary blastoma. Tumor sequencing identifies somatic alterations but does not by itself determine whether an alteration is germline; refer the patient for genetic counseling and germline testing when the clinical or molecular findings warrant it. ^[21]

Have every difficult pediatric or adolescent case reviewed by a pathologist with pediatric sarcoma expertise. Central review can prevent protocol misdirection when a limited biopsy resembles another small round-cell tumor, and registry experience shows that molecular testing can clarify lesions initially classified as rhabdomyosarcoma or left indeterminate. ^[26] The final report should state the histologic subtype or pattern, the extent and distribution of rhabdomyoblastic differentiation, necrosis and mitotic activity when appreciable, immunophenotypic results with staining localization, FOXO1 rearrangement or fusion status, other defining fusion results, and clinically relevant sequence alterations. For a resection, document margin status and the distance to the closest margin; when preoperative therapy has been given, describe treatment effect, including viable tumor, necrosis, fibrosis, and therapy-associated change. Do not assign formal stage, group, or treatment risk in the pathology diagnosis; provide the data required for those determinations instead.

Rhabdomyosarcoma is assigned risk by integrating three different descriptions of disease: anatomic extent (TNM), completeness of local resection (Intergroup Rhabdomyosarcoma Study [IRS] clinical group), and biologic and clinical relapse risk (cooperative-group risk group). These systems answer different questions and must not be substituted for one another. ^[73]

TNM-based clinical staging

Contemporary pediatric and adolescent RMS staging records the primary tumor, regional nodes, and distant metastases. T describes the primary site, local invasiveness, and maximum tumor dimension; N records regional nodal involvement; and M records distant disease. The clinically assigned categories are based on pretreatment examination and imaging, whereas pathologic nodal status is assigned only after tissue assessment. ^[66]

For the primary tumor, T1 generally denotes a tumor confined to its anatomic site and T2 a tumor that invades adjacent structures. Tumor size is conventionally divided at 5 cm, producing T1a/T2a for tumors ≤5 cm and T1b/T2b for tumors >5 cm in protocols using the size-qualified TNM schema. Because RMS protocols and registry systems may differ in the precise site and invasiveness definitions, the protocol-specific TNM table should accompany the stage in the clinical record. Tumor size and invasiveness remain clinically meaningful because larger, invasive tumors are more difficult to control locally and are associated with poorer outcome. ^[70][72]

Primary site modifies the T category and the subsequent risk assignment. Favorable sites include the orbit, nonparameningeal head and neck, and genitourinary sites outside the bladder and prostate; unfavorable sites include parameningeal disease, bladder or prostate, extremity, perineal or perianal sites, and other sites categorized as unfavorable by the cooperative-group protocol. Site is not merely descriptive: it reflects patterns of local extension, the feasibility of complete local control, and the propensity for regional or distant spread. ^{[71][73][75][77]}

N0 means that regional nodes are not involved clinically or radiologically; N1 means regional nodal disease identified clinically or radiologically, with pathologically confirmed disease recorded as pN1. The regional basin is the first major draining lymphatic basin, and in-transit nodes between the primary tumor and that basin are treated as regional N1 disease. Nodes beyond the regional basin are classified as distant metastatic disease. ^[66][67] Imaging cannot reliably exclude microscopic nodal disease: in pediatric soft-tissue sarcoma, surgical sampling has detected nodal involvement in 16-33% of patients whose nodes were radiologically negative. ^[66]

Nodal staging therefore changes both prognosis and treatment planning. Regional nodal involvement is particularly adverse in alveolar RMS and in tumors with a PAX3/7::FOXO1 fusion, and it is associated with inferior failure-free and overall survival. ^[66] Evaluate regional nodes with targeted biopsy when they are suspicious or indeterminate; consider sentinel-node or systematic regional sampling in high-risk lymphotropic presentations, especially extremity RMS, paratesticular RMS in patients older than 10 years, and fusion-positive RMS. ^[66][67]

M0 indicates no distant metastases detected at diagnosis, whereas M1 indicates distant disease. Distant sites include the lungs, bone, bone marrow, distant nodes, and other nonregional compartments. Metastatic RMS is biologically and clinically distinct from localized disease: in a large analysis of alveolar RMS, localized tumors had 5-year event-free and overall survival of 56% and 65%, compared with 18% and 22% for metastatic tumors. ^[70] Bone or marrow metastases and a PAX3::FOXO1 fusion are particularly adverse features among patients with metastatic alveolar RMS. ^[70]

IRS clinical groups

The IRS clinical group system is based primarily on what the biopsy and local procedure leave behind, not on the TNM anatomic stage. Group I is a completely resected tumor with no involved regional nodes; Group II is a grossly resected tumor with microscopic residual disease, involved regional nodes that have been resected, or both; and Group III is biopsy-only or incompletely resected disease with gross residual tumor. Group IV denotes metastatic disease at diagnosis, regardless of the amount of local tumor removed. The system therefore captures residual local and regional tumor burden after the initial operation, whereas TNM is assigned from pretreatment anatomy. ^[73][74]

A patient may consequently have a favorable TNM stage but IRS Group II or III disease if the tumor cannot be removed completely, or a higher anatomic stage with Group I local resection if an operation removes the visible primary tumor. Group assignment should be recorded only after the biopsy and operative or pathologic findings are reconciled; a pathology report should provide margins, residual disease, and nodal findings rather than infer the IRS group from histologic appearance alone. ^[74]

COG and European risk stratification

The Children's Oncology Group (COG) risk system combines age, primary site, tumor size, nodal status, distant metastases, IRS group, histologic pattern, and, more recently and more reliably than alveolar morphology, FOXO1 fusion status. Fusion-positive RMS, particularly PAX3::FOXO1-positive disease, is assigned greater biologic risk because the fusion identifies a clinically aggressive molecular class; alveolar architecture without a FOXO1 fusion should not be treated as equivalent to fusion-positive RMS. ^[65][70]

COG categories are commonly expressed as very-low-, low-, intermediate-, and high-risk disease, although clinical summaries often group the latter three as low, intermediate, and high risk. Very-low and low-risk disease generally consists of localized, FOXO1 fusion-negative tumors in favorable sites, with small, node-negative tumors and complete or near-complete local control. Intermediate-risk disease includes localized tumors with one or more adverse clinical features, an unfavorable site, size >5 cm, age ≥10 years, regional N1 disease, IRS Group III residual disease, or FOXO1-positive biology without distant metastases. High-risk disease is dominated by metastatic disease, particularly when accompanied by FOXO1 fusion, bone or marrow involvement, older age, or other adverse molecular features. Exact boundaries depend on the COG protocol and trial era; the treating protocol, not a generic label, determines eligibility and treatment intensity. ^[73][70]

Histology modifies risk only through an integrated morphologic and molecular assessment. Fusion-positive alveolar RMS is a high-risk biologic entity, whereas fusion-negative alveolar-pattern tumors are heterogeneous and cannot be assigned risk from architecture alone. MYOD1-altered spindle cell/sclerosing RMS and TP53-altered or anaplastic tumors are additional adverse biologic subsets recognized in contemporary risk models, although their classification may vary by protocol and their evidence base is less mature than that for FOXO1 fusion status. ^[65][73]

European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) schemas use many of the same variables, site, age, size, nodal disease, metastases, histology or fusion status, and IRS group, but combine them differently and may use different labels such as standard, high, and very-high risk. These categories are not numerically interchangeable with COG categories: when 1,993 EpSSG-trial patients were reclassified, 66.8% of patients classified as standard, high, or very-high risk by EpSSG were classified as intermediate risk by COG, and only 57.3% would have received comparable chemotherapy intensity under both systems. ^[63] CWS and other cooperative groups likewise use related but nonidentical algorithms. Report the cooperative group and protocol version whenever a risk category is cited. ^[63][66]

Do not conflate these systems. TNM describes pretreatment anatomy; IRS group describes residual disease after biopsy or resection; COG, EpSSG, and other cooperative-group categories estimate relapse risk and select a protocol-defined treatment intensity. A single patient must therefore have all three recorded, for example, “T2bN1M0, IRS Group III, COG intermediate risk”, rather than one system being used as shorthand for the others. ^[63][66][73]

Treatment planning for rhabdomyosarcoma begins in a disease-specific multidisciplinary team: pediatric or adult sarcoma oncology, sarcoma surgery, radiation oncology, expert radiology and pathology, rehabilitation, fertility medicine, nursing, and psychosocial services. Referral to a sarcoma reference center is particularly important for adults, in whom the disease is rare, outcomes are poorer, and treatment evidence is largely extrapolated from pediatric programs; a systematic review found that most adult studies were retrospective and strongly recommended specialized sarcoma-center care. ^[85] High-volume networks can achieve comparable survival across institutions when protocol-based diagnostic and treatment support is available, but complex local control should remain centralized. ^[95]

Obtain diagnostic tissue after complete staging MRI and before definitive treatment, unless an immediately threatening obstruction, hemorrhage, or neurologic complication requires urgent intervention. The biopsy tract must remain within tissue that can be removed during definitive local therapy. ^[81] The pathology report should establish subtype and molecular class, particularly FOXO1 fusion status where relevant, because treatment risk is assigned from the integrated clinical, anatomic, residual-disease, and biologic profile rather than from morphology alone. COG and EpSSG do not assign risk identically: a reclassification study found that only 57.3% of patients would have received comparable chemotherapy intensity under both systems. ^[63]

For most newly diagnosed patients, the sequence is induction multi-agent chemotherapy, early response assessment, definitive local control with surgery, radiotherapy, or both, and completion chemotherapy; high-risk programs may add maintenance therapy. The precise sequence differs among Children’s Oncology Group (COG), European Paediatric Soft Tissue Sarcoma Study Group (EpSSG), Cooperative Weichteilsarkom Studiengruppe, and adult sarcoma programs. EpSSG RMS2005 used nine chemotherapy cycles with local therapy after course 4 for localized disease and after course 6 for metastatic disease, whereas COG protocols commonly use alternating VAC/VI-based treatment and protocol-specific local-control timing. ^[81] Adult treatment should be individualized in a sarcoma center: retrospective data suggest that adequate exposure to pediatric-type regimens may be associated with better survival, but this evidence is confounded and does not establish one universal adult regimen. ^[85]

Use the following framework as a treatment-intensity guide; the formal TNM stage, IRS clinical group, and cooperative-group risk assignment remain separate clinical documents and should not be replaced by the response category.

Low-risk disease permits the greatest reduction in treatment burden. In an international cohort of completely resected, nonalveolar tumors outside paratesticular, uterine, and vaginal sites, five-year overall survival was 92.5%; the investigators concluded that vincristine-actinomycin-D for 24 weeks may be considered for tumors smaller than 5 cm, but this approach remains protocol-dependent rather than a universal adult recommendation. ^[91] EpSSG standard-risk data likewise support reducing cumulative alkylator exposure when radiotherapy provides local control, although omission of radiotherapy was associated with inferior event-free survival overall and inferior overall survival in orbital tumors. ^[71]

Intermediate-risk disease requires deliberate comparison of surgery and radiotherapy rather than reflexive maximal resection. Delayed primary excision after induction chemotherapy can reduce radiation dose in selected tumors, but surgery may sacrifice a functioning organ, limb, or other vital structure; in a COG analysis, loss of vital organ or function occurred in 22% of patients undergoing delayed excision. ^[92] For this reason, preserve the organ when oncologically safe, and discuss the expected effects on growth, endocrine function, continence, fertility, limb function, dentition, appearance, and neurocognition before local therapy. In female genital-tract RMS, an international COG-EpSSG-CWS consensus advises against initial complete resection, recommends fertility preservation consideration for all patients, and reserves brachytherapy for persistent vaginal or cervical disease after induction; persistent corpus-uteri disease may require hysterectomy. ^[82]

High-risk disease justifies greater systemic intensity because relapse risk is driven by occult dissemination even when imaging shows a localized primary. EpSSG established maintenance with vinorelbine and low-dose oral cyclophosphamide after initial therapy for high-risk RMS; the randomized trial showed improved five-year overall survival, and mature follow-up confirmed the survival benefit. ^[89][88] The regimen used in the EpSSG RMS2005 trial is:

This maintenance regimen is not biologically innocuous: additional gonadal dysfunction has been associated with oral cyclophosphamide exposure, particularly in males diagnosed after age 5 years or receiving prolonged exposure. Discuss sperm cryopreservation, ovarian tissue or oocyte strategies when feasible, endocrine counseling, and long-term gonadal surveillance before treatment begins. ^[97]

Metastatic RMS requires systemic therapy from the outset and local control of the primary and metastatic deposits when feasible. The EpSSG MTS2008 strategy used four cycles of IVA plus doxorubicin, followed by five cycles of IVA and 12 cycles of low-dose cyclophosphamide/vinorelbine maintenance; pooled three-year event-free and overall survival remained only 35.5% and 49.3%, respectively. Because that study was not designed to separate the effects of induction intensification from maintenance, do not interpret an early response as proof that the treatment has altered prognosis. ^[87] Offer a clinical trial whenever possible, especially for FOXO1-positive, MYOD1-altered, TP53-altered, node-positive, bone/marrow, or widely metastatic disease. FaR-RMS is an example of an international platform testing systemic combinations, maintenance duration, radiotherapy strategies, molecular risk assignment, imaging biomarkers, and patient-reported quality of life across pediatric and adult patients. ^[86]

Assess the primary tumor with MRI, metastatic sites with protocol-appropriate PET and/or MRI, and pulmonary disease with diagnostic chest CT. EpSSG imaging guidance recommends initial response assessment after two to three chemotherapy courses, corresponding to approximately 6-9 weeks, and reassessment before local therapy when metastatic disease is present. ^[81] Measure disease consistently, preferably with RECIST 1.1 one-dimensional measurements and expert or central review when progression is suspected. A 20% increase in the sum of target-lesion diameters, a new lesion, or unequivocal enlargement of a non-target lesion defines progression; stable disease, partial response, and complete response do not reliably separate survival groups in pediatric RMS, whereas confirmed progression is the principal trigger for changing systemic therapy. ^[81][94] Do not substitute radiologic response for TNM stage, IRS group, FOXO1 status, or cooperative-group risk assignment; these variables determine treatment intensity even when the mass shrinks substantially.

Pearl: The safest plan is not the most aggressive local operation or the largest chemotherapy dose; it is protocol-concordant systemic therapy with risk-adapted local control, explicit fertility and late-effect planning, and a trial discussion whenever standard treatment is unlikely to overcome the disease biology.

Local control should be planned at diagnosis by a multidisciplinary sarcoma team, because the value of a margin depends on what its achievement costs: local control must be weighed against vision, sphincter and bladder function, fertility, endocrine function, facial growth, limb function, and long-term organ toxicity. International consensus for bladder and prostate RMS explicitly incorporates age, tumor size and location, nodal involvement, and access to local expertise and technology. ^[98]

Biopsy tract and operative principles. Place the biopsy incision, drain site, and needle path so that they can be removed en bloc with the definitive specimen. Keep the tract within one anatomic compartment; do not traverse an uninvolved joint, neurovascular bundle, or potentially preservable organ. Mark the tract for the surgeon and pathologist, and document its relationship to fascia and adjacent structures. These measures prevent a contaminated tract from becoming an unplanned second field of disease and preserve the option of complete resection. The operative objective, when anatomically and functionally acceptable, is complete excision with negative microscopic margins; the intent of surgery is not to obtain a margin at any cost, but to avoid unacceptable loss of function or cosmetic form. ^[41]

A complete resection with negative margins can reduce residual local disease and, in selected favorable-risk tumors, may permit omission of radiation under a cooperative-group protocol. That conclusion cannot be generalized from retrospective surgical series: patients selected for resection are more likely to have smaller, accessible, and biologically favorable tumors. A positive microscopic margin is not automatically an indication for radical reoperation. Re-resect only when the residual focus is discrete, the procedure is technically safe, and the expected functional gain from avoiding radiation exceeds the morbidity of another operation. Re-resection is particularly attractive when radiation carries an unusually high secondary-cancer risk, such as in a patient with germline TP53 -associated Li-Fraumeni syndrome. ^[25]

Do not perform routine radical surgery, mutilating compartmental resection, or initial exenteration merely to convert a biopsy-only or gross-residual tumor into a surgical group with no visible disease. RMS is frequently highly responsive to multimodality treatment, and a technically complete operation may sacrifice an eye, facial growth centers, bladder, bowel, reproductive organs, urinary or anal sphincters, or major neurovascular structures without proving superior disease control. Orbital exenteration belongs to exceptional salvage decisions rather than routine initial management; in a relapsed orbital cohort, exenteration was used among salvage treatments, not as the standard initial local-control procedure. ^[49]

Delayed and organ-sparing surgery. After induction treatment, reassess with contrast-enhanced MRI and review the images with the surgeon, radiation oncologist, radiologist, and pathologist. Consider delayed primary excision when the tumor has become smaller or better demarcated, when resection can remove residual disease without major functional loss, or when surgery may reduce the volume or dose of radiation. Delayed primary excision is not a mandate to remove a radiographic scar: a complete clinical response may reflect treatment effect, and imaging cannot reliably distinguish sterilized tissue from viable RMS. Conversely, persistent or enlarging enhancement, a focal residual mass, or discordant clinical and imaging findings may justify a targeted second-look biopsy or resection. A small retrospective pediatric cohort found comparable event-free survival after delayed and upfront resection, but its sample size and selection make it feasibility evidence rather than proof of equivalence. ^[41]

Use organ-sparing surgery selectively in accessible genitourinary, genital, and superficial tumors. Vaginal or cervical lesions may be approached transvaginally, vaginoscopically, laparoscopically, or through another limited route when the lesion is localized and the surrounding organs can be preserved; published reports describe these approaches as feasible in carefully selected patients, but follow-up is short and they do not establish a universal technique. ^{[102] [12]} Avoid initial radical hysterectomy, cystectomy, prostatectomy, or pelvic exenteration when induction response and conformal radiation offer a reasonable chance of control with preservation of urinary, sexual, reproductive, and bowel function. Bladder and prostate decisions require explicit discussion of the limited long-term functional data and the patient’s age and developmental stage. ^[98]

Sample or dissect regional nodes when the site, biology, tumor size, or imaging raises a meaningful risk of occult nodal disease and the result will change the radiation field or risk assignment. Use a targeted biopsy, sentinel-node procedure, or systematic sampling according to the anatomic basin and protocol. Imaging alone can misclassify nodal status: in bladder/prostate RMS, surgical sampling after induction identified tumor in 6 of 37 patients considered node-negative on imaging, and the findings changed local therapy in 9 of 14 patients with imaging-pathology discordance. ^[44] Do not perform an extensive nodal dissection solely for staging when sampling will answer the question; in the same bladder/prostate series, surgical nodal assessment did not improve locoregional outcome compared with imaging-based staging. ^[44]

A second-look procedure is reasonable when the first operation was intentionally limited, when induction treatment has converted an unresectable lesion into a potentially organ-preserving target, or when a residual abnormality would alter the choice between further surgery and radiation. It is not a routine exploratory operation after every partial response. In parameningeal, orbital, pelvic, and biliary RMS, the procedure must be designed around the route of spread and the structure at risk rather than around an abstract margin goal.

Radiation technique and timing. External-beam radiation remains the principal nonsurgical local-control treatment for gross residual, unresectable, anatomically constrained, or margin-positive disease. Start it at the protocol-defined point after induction treatment and before prolonged treatment delay when local anatomy or residual disease requires prompt control. Timing is not interchangeable across protocols: a recent retrospective proton series treated patients according to RMS2005 or FaR-RMS protocols, with radiation beginning a median of 13 weeks after chemotherapy initiation; initiation at or after 14 weeks was not independently associated with worse outcomes after adjustment, but the authors caution that the finding requires validation. ^[99]

Define the clinical target volume from the pretreatment tumor extent, routes of microscopic spread, biopsy tract when relevant, and involved nodes, then add a protocol-specified margin for setup and motion. Do not shrink the target solely because MRI shows a complete or near-complete response; treatment effect does not prove eradication of microscopic disease. Gross residual tumor requires coverage of the residual mass and the appropriate pretherapy volume, while postoperative planning must account for the original tumor bed, surgical clips, margin status, and any contaminated tract. Nodal target volumes should follow documented nodal involvement and the applicable protocol rather than imaging appearance alone.

Use three-dimensional conformal planning, intensity-modulated radiation therapy or volumetric-modulated arc therapy, and image-guided radiation therapy to shape dose around the target and verify daily setup. Retrospective sinonasal RMS data associated IMRT/VMAT and primary chemoradiotherapy with better local and survival outcomes, but treatment selection and confounding prevent causal inference. ^[45] Image guidance is especially valuable when targets are adjacent to the orbit, skull base, bowel, bladder, kidneys, liver, or growing bone.

Consider proton therapy when its dose distribution can reduce clinically meaningful exposure to developing organs without compromising target coverage. Proton therapy is not intrinsically superior for tumor control: in a retrospective series of nonmetastatic RMS treated definitively with protons, local failures occurred within the high-dose region, and outcome was driven primarily by disease factors such as parameningeal location, intracranial extension, and advanced T stage. ^[99] Select protons through comparative planning and a protocol review, accounting for range uncertainty, anatomic growth, motion, and the possibility that target geometry will change during treatment.

Use brachytherapy only in selected anatomic circumstances, generally as a highly localized treatment combined with surgery rather than as a substitute for appropriate coverage of extensive disease. In long-term survivors studied after orbital and head-and-neck treatment, brachytherapy was delivered with surgery as part of an organ-preserving AMORE strategy, whereas photon and proton external-beam radiation were used with or without surgery. ^[103] In vaginal or cervical RMS, brachytherapy can be considered for persistent, localized disease after induction when an applicator can cover the target while sparing the bladder, rectum, and developing reproductive organs. ^[41]

Selected intraoperative approaches, such as fluorescence-assisted identification of uncertain residual tissue, may help guide re-resection when a margin is difficult to localize, but they remain adjuncts to an oncologic operation and do not replace pretreatment imaging, pathology, or protocol-directed radiation. The first reported pediatric use of pegulicianine in Li-Fraumeni-associated RMS was undertaken because the margin location was uncertain and re-resection was preferred to radiation exposure. ^[25]

Do not apply a universal radiation-dose table to RMS. Prescription dose, boost policy, target margins, nodal coverage, and normal-tissue constraints vary with protocol, age, site, response, residual disease, surgery, and prior irradiation. Plan around growth, fertility, hypothalamic-pituitary and thyroid function, cognition, hearing, vision, renal function, bowel and bladder function, and future reconstructive options. Dose-toxicity data provide planning context rather than universal thresholds: in long-term head-and-neck survivors, mean doses above 40 GyEQD2 to the orbit, above 10 GyEQD2 to the lacrimal gland, and above 6 GyEQD2 to the lens were associated with more than a 20% probability of the corresponding ocular toxicities; retinopathy and optic neuropathy occurred after maximum doses above 40 and 53 GyEQD2, respectively. ^[103] Facial-bone growth is also dose sensitive, with increased deformation risk reported across individual facial bones at approximately 26-43 GyEQD2 and a 50% probability of deformation at approximately 44-55 GyEQD2. ^[104]

Radiation omission is a carefully bounded de-escalation strategy, not a consequence of radiographic response alone. Consider it only when the patient meets the exact favorable-risk, fusion- and protocol-defined criteria, has complete resection with appropriate pathologic assessment, and can undergo close surveillance. Reconsider omission when margins are uncertain, the tumor is biologically adverse, nodal disease is present, the site is unfavorable, or the operation leaves gross or clinically meaningful microscopic disease. Even when radiation is omitted, document a survivorship plan that monitors growth, endocrine and reproductive function, organ-specific function, and local recurrence risk. Local control is successful only when the patient remains both disease-free and functionally intact.

Systemic treatment is risk-adapted multiagent chemotherapy delivered with planned local control, not chemotherapy alone. EpSSG and COG both use an alkylating agent with vincristine and dactinomycin (actinomycin-D); European protocols commonly use ifosfamide, whereas North American protocols commonly use cyclophosphamide. No induction combination has established superiority between European IVA and North American VAC backbones in localized high-risk disease, although their renal, gonadal, marrow, and bladder toxicities differ. ^[86]

Frontline regimens

For low-risk disease, de-escalation is justified only when the full protocol definition is satisfied: favorable clinical features, fusion-negative biology where required, complete or functionally adequate local control, and no adverse nodal or metastatic findings. EpSSG RMS2005 reported 5-year event-free survival of 93.7% and overall survival of 96.7% in its low-risk cohort while confirming the 22-week VA approach. ^[84] Do not convert an alveolar appearance, a radiographic response, or a small tumor by itself into eligibility for reduced therapy; FOXO1 fusion status and the cooperative-group risk algorithm determine treatment intensity. ^[86]

For standard- and high-risk disease, preserve dose intensity unless toxicity requires a protocol-defined modification. Cumulative alkylator exposure matters: cyclophosphamide and ifosfamide can impair fertility, and ifosfamide can produce renal tubular injury before a fall in estimated glomerular filtration rate. In a prospective exploratory pediatric cohort receiving ifosfamide, acute proximal tubular toxicity occurred during chemotherapy in every participant, while chronic toxicity developed in 8 of 13 evaluable children and reduced glomerular filtration in 7. ^[115] Record cumulative cyclophosphamide and ifosfamide doses, urine output, urinalysis, serum creatinine, estimated glomerular filtration rate, electrolytes, bicarbonate, phosphate, magnesium, and tubular markers when available. Adjust or withhold nephrotoxic therapy for clinically significant renal deterioration, and involve nephrology early when tubular wasting, persistent proteinuria, glycosuria, acidosis, or declining filtration develops.

Anthracyclines require a separate lifetime-exposure record. Obtain baseline cardiac assessment before doxorubicin, repeat echocardiography according to cumulative exposure and symptoms, and avoid adding doxorubicin to localized disease merely to intensify therapy: RMS2005 omitted doxorubicin from its high-risk localized strategy, whereas EpSSG retains IVADo for very-high-risk and metastatic groups because of their poor prognosis and prior evidence of doxorubicin activity. ^[84] This is a protocol distinction rather than a settled biological rule; COG and EpSSG risk groups are not interchangeable, and their treatment boundaries differ. ^[86]

Protocol additions and maintenance

Irinotecan is a protocol-specific alternative to part of the VAC backbone rather than a universal replacement for cyclophosphamide. COG uses VAC alternating with VI, where VI means vincristine plus irinotecan; European FaR-RMS is evaluating irinotecan added to IVA or IVADo in newly diagnosed high- or very-high-risk disease after phase Ib dose finding. ^[86] Use irinotecan only with the schedule and supportive-care plan specified by the trial or cooperative-group protocol, because the evidence does not establish one universal frontline dose or duration across programs.

Doxorubicin-containing IVADo is reserved for selected very-high-risk or metastatic presentations in European programs. EpSSG uses four courses of IVADo followed by five courses of IVA, but the survival advantage attributable specifically to doxorubicin remains uncertain because the available metastatic studies combined induction intensification, local therapy, and maintenance. ^[86] Discuss cumulative anthracycline exposure, cardiac surveillance, fertility, and the possibility that trial participation may be preferable to empiric escalation.

Maintenance is the clearest positive randomized systemic-therapy signal beyond induction. In the EpSSG RMS2005 high-risk trial, patients received six 28-day cycles of vinorelbine 25 mg/m² intravenously on days 1, 8, and 15 plus cyclophosphamide 25 mg/m² orally once daily on days 1-28; mature follow-up confirmed improved 10-year disease-free survival and overall survival compared with observation. ^[88] This benefit applies to the trial-defined high-risk population after initial therapy and local control, not automatically to every patient with residual imaging abnormality or metastatic disease. The added alkylator exposure is clinically meaningful: in a French RMS2005 survivorship analysis, exocrine gonadal dysfunction occurred in 37% of evaluated male survivors and was associated with maintenance cyclophosphamide exposure. ^[97]

Other maintenance strategies should remain trial-bound. The randomized CWS-2007-HR study found that 25 weeks of oral trofosfamide, idarubicin, and etoposide did not improve event-free or overall survival. ^[109] Retrospective reports of long-term maintenance in metastatic disease are vulnerable to selection and immortal-time bias and should not displace randomized or prospective protocol evidence. ^[113]

Targeted and immune approaches

Do not present targeted therapy or immunotherapy as an established substitute for frontline VAC, VA, IVA, or IVADo. Temsirolimus, an mammalian target of rapamycin inhibitor, was feasible at 15 mg/m² intravenously on days 1, 8, and 15 when added to VAC/VI, but the randomized ARST1431 phase III trial found no significant improvement in 3-year event-free survival with temsirolimus. ^[90] Its toxicities included more grade 3-4 anemia and similar substantial rates of neutropenia and lymphopenia; use belongs in a clinical trial, not routine frontline practice.

Pazopanib, an oral multitargeted tyrosine-kinase inhibitor, anti-IGF-1R antibodies, immune-checkpoint inhibitors, antiangiogenic agents, and other pathway-directed treatments remain investigational in newly diagnosed RMS. Their rationale derives from recurrent pathway alterations and preclinical or early-phase activity, but current reviews emphasize the need for prospective studies to establish clinical significance rather than recommending these agents over cytotoxic chemotherapy. ^[107] A negative or unselected biomarker result should not prompt off-label substitution for curative-intent chemotherapy; enroll patients with adverse molecular disease in a disease-specific trial whenever possible.

Administration and supportive care

Place reliable central venous access before repeated vesicant or irritant chemotherapy, frequent blood sampling, transfusion support, and rapid treatment of febrile neutropenia. Confirm catheter position and establish a line-care plan; fever during chemotherapy requires immediate institutional febrile-neutropenia management rather than outpatient observation. Give antiemetic prophylaxis matched to the emetogenicity of the planned combination, with a serotonin-receptor antagonist and dexamethasone when appropriate; an international pediatric consensus specifically judged the benefits of dexamethasone antiemesis to outweigh its risks for children receiving chemotherapy for RMS. ^[114]

Before every course, review blood counts, renal and hepatic tests, bilirubin, electrolytes, urinalysis, hydration status, neuropathy, mucositis, infection, and catheter function. During ifosfamide, monitor for encephalopathy and proximal tubular dysfunction; during cyclophosphamide, maintain protocol-directed hydration and bladder protection; during vincristine, examine gait, strength, reflexes, constipation, ileus, jaw pain, and neuropathic symptoms; during dactinomycin, assess mucositis, hepatic injury, and radiation-enhancement risk; during doxorubicin, reassess cardiac symptoms and cumulative dose. Hold or modify treatment according to the governing COG, EpSSG, or local trial protocol rather than applying a single cross-platform dose-modification table.

Discuss fertility preservation before the first alkylator or anthracycline whenever developmentally and clinically feasible. Refer males for sperm banking or testicular tissue options and females for oocyte, embryo, or ovarian-tissue consultation according to age, pubertal status, urgency, and local expertise. Explain that maintenance cyclophosphamide adds gonadal risk after ifosfamide-based induction, particularly in patients older than five years or those receiving prolonged exposure. ^[97] Document reproductive goals, endocrine follow-up, and the cumulative doses that will determine long-term survivorship surveillance.

Pearl: Use the least intensive regimen that is safe for the molecular and clinical risk group, but do not reduce dose intensity or omit an alkylator, anthracycline, or maintenance phase outside the protocol population that established it.

Local treatment should be planned from the pretreatment map, not from the residual mass after chemotherapy. Obtain high-quality contrast-enhanced MRI with diffusion-weighted sequences and include the relevant regional nodal basins; use FDG PET/CT or PET/MRI when nodal or distant disease is suspected, and retain diagnostic-quality chest CT because small pulmonary lesions may be missed by PET. ^[81] Re-image after 2-3 chemotherapy courses, approximately 6-9 weeks, and before local therapy; stable or partial response alone should not trigger a change in systemic treatment, whereas confirmed progression does. ^[81]

Regional nodes deserve site-specific handling rather than routine dissection. MRI should cover the complete draining basin, and FDG-PET combined with anatomical imaging can improve assessment, although FDG uptake is not cancer-specific and equivocal nodes require tissue confirmation when the result would change therapy. ^[66][81] In bladder/prostate RMS, EpSSG found tumor in 6 of 37 patients considered node-negative by imaging, but surgical nodal assessment did not improve locoregional outcome overall; therefore, sample targeted nodes when staging will alter radiation or systemic risk assignment, not indiscriminately. ^[44]

Radiation planning should use the pretreatment tumor extent, biopsy tract, involved nodes, surgical bed, and routes of microscopic spread rather than the post-chemotherapy volume alone. For head and neck tumors, contour the optic apparatus, lenses, lacrimal glands, cochleae, brain, pituitary-hypothalamic axis, teeth, and facial bones as organs at risk; use image guidance and compare photon and proton plans for integral dose and clinically relevant sparing. ^[117][81] In peritoneal metastatic disease requiring whole-abdominopelvic radiation, consensus delineation includes the diaphragmatic dome, liver surface and porta hepatis, gallbladder, falciform ligament, and bladder while excluding uninvolved retroperitoneum and kidneys; use 4D-CT to account for respiratory motion when available. ^[100]

Do not interpret a radiographic complete response as proof of eradicated viable tumor, and do not escalate surgery solely because a residual MRI abnormality persists. Reassess persistent focal abnormalities in multidisciplinary conference and consider delayed resection or biopsy only when the result will alter local treatment and the procedure preserves meaningful function. ^[81][116]

Drug dosing in this site-specific section is not separately defined: chemotherapy should follow the active pediatric, adolescent-young adult, or adult RMS protocol selected by the treating sarcoma team, rather than an anatomic-site regimen improvised outside protocol.

Pearl: In RMS, the safest local-control plan is rarely the most radical operation: map the full route of spread, stage the nodes when the site warrants it, preserve function deliberately, and reserve surgery for disease that can be removed without sacrificing a functioning organ, nerve, vessel, or reproductive system.

Relapse means return of RMS after a period of remission; refractory disease means persistent or progressive tumor during initial therapy or failure to achieve the expected disease control. Progression denotes worsening during treatment or surveillance and may occur without an intervening complete response ^[126]. Classify the event anatomically because the classification determines whether cure remains a realistic goal through local treatment, systemic therapy, or both:

• Local relapse: recurrence at the original primary site or operative bed without regional nodal or distant disease.
• Regional relapse: recurrence in regional lymph nodes or immediately contiguous regional tissues without distant metastasis.
• Distant relapse: hematogenous or nonregional recurrence, including lung, bone, marrow, distant nodes, pleura, or other organs.
• Combined relapse: simultaneous local or regional recurrence and distant disease.

A new mass is not automatically recurrent RMS. Obtain image-guided core biopsy whenever the result is technically feasible and will alter treatment, particularly after radiotherapy or when imaging shows an isolated, enlarging, or atypical lesion. Biopsy can distinguish viable RMS from treatment-related fibrosis, necrosis, infection, a second malignancy, or a different sarcoma; send viable tissue for morphology, myogenic immunohistochemistry, FOXO1 fusion assessment, and sequencing directed by the morphology and prior molecular findings ^[49]. Avoid biopsy only when the procedure carries disproportionate risk and the clinical and radiologic evidence is unequivocal, or when an immediately threatening complication requires urgent treatment before tissue can be obtained.

Restage the whole patient rather than imaging only the symptomatic site. Obtain contrast-enhanced MRI of the primary and regional compartments, or CT when MRI is unsuitable, together with thin-section chest CT. Add brain or spine MRI for neurologic symptoms or a parameningeal, skull-base, or spinal concern; use FDG-PET/CT or whole-body MRI selectively for equivocal nodal, osseous, or multifocal disease. PET/CT is an adjunct, not a substitute for chest CT, because a reported pediatric series found that PET/CT missed a 0.6-cm pulmonary nodule seen on chest CT ^[55]. Re-review the original and recurrent specimens with a sarcoma pathologist, reconcile fusion testing with morphology, and repeat molecular testing when the original sample was scant, degraded, or fusion status was never established. FOXO1 fusion status is particularly relevant because it was the most important prognostic characteristic after metastatic status in a Children's Oncology Group analysis of metastatic RMS ^[126].

Discuss prognosis using the disease course rather than a single label such as “relapsed.” A later first event is generally more favorable than an early one: in the INSTRuCT cohort, patients who remained disease-free after relapse were more likely to have relapsed more than 18 months after diagnosis ^[126]. Initial risk group still matters because relapse after initially localized, favorable-risk disease may be amenable to durable local control, whereas relapse after upfront metastatic disease is biologically and clinically more difficult. In the largest reported cohort of first relapse or progression after metastatic RMS, 3-year overall survival after the event was 8.0% ^[126].

Record the site and burden of recurrence precisely. An isolated resectable local recurrence, a solitary lung lesion, and disseminated bone-marrow disease are not interchangeable clinical problems. At initial diagnosis, bone or marrow involvement, an unfavorable primary site, three or more metastatic organ systems, and age younger than 1 year or at least 10 years constitute the classic Oberlin adverse factors; patients with zero factors had a reported 3-year event-free survival of 50%, compared with 5% when all four were present ^[126]. At relapse, burden, nodal involvement, and the time to recurrence should be integrated with FOXO1 status, particularly PAX3::FOXO1 versus fusion-negative disease. Interpret these variables as prognostic, not as a validated rule that determines an individual salvage regimen: the INSTRuCT database lacked detailed information on treatment delivered after relapse, secondary surgery, and radiotherapy ^[126].

Salvage chemotherapy is not a single standard regimen and must not be confused with frontline VAC, IVA, or other risk-adapted therapy. Choose treatment according to prior agents, duration of response, residual organ function, marrow reserve, and whether local control is possible. Vinorelbine with continuous low-dose cyclophosphamide is supported by retrospective salvage experience: in 18 heavily pretreated children, disease control lasting longer than 10 months occurred in six patients, while neutropenia occurred in 89%; dose reductions were frequently required ^[127]. The investigators concluded that starting at approximately 80% of the standard dose may be appropriate in heavily pretreated patients ^[127]. Use irinotecan-temozolomide or topotecan-cyclophosphamide only within an accepted cooperative-group or institutional salvage protocol, with explicit monitoring for diarrhea, myelosuppression, infection, renal injury, and cumulative toxicity. Reassess after a protocol-defined interval; confirmed progression, rather than stable disease or a modest radiologic response alone, should trigger a change in systemic strategy.

Local therapy can convert selected relapse into a potentially curative treatment, but selection is critical. Reoperate when all visible disease can be removed with acceptable functional and oncologic morbidity; do not perform radical exenteration, amputation, or organ sacrifice solely because a recurrence is present. Consider reirradiation only after reconstructing the prior dose distribution and estimating the risk to growing bone, optic structures, brain, spinal cord, bowel, bladder, gonads, and other previously irradiated organs. Ablation is reserved for small, technically accessible lesions and should not be assumed equivalent to complete surgical excision. For metastatic disease at presentation, international consensus recommends definitive treatment of the primary and involved regional nodes after neoadjuvant chemotherapy and recommends local treatment of all disease sites when feasible, although the supporting evidence is limited ^[128].

Targeted and immune approaches remain investigational. mTOR inhibition, IGF-1R blockade, MEK inhibition, CDK-directed therapy, FGFR-directed agents, ALK or NTRK inhibition, and strategies against PAX3::FOXO1 or PAX7::FOXO1 should be considered only when a molecularly matched trial or protocol supports them; a target identified by sequencing does not establish clinical efficacy. Current development programs include RAS-pathway, ALK, NTRK, FGFR, MSI-high, and fusion-directed strategies ^[129]. MEK inhibitors, possibly combined with BRAF or PI3K inhibition, are being proposed for clinical evaluation rather than accepted as standard salvage therapy ^[36]. CAR-T cells and antibody-drug conjugates directed at FGFR4 or B7-H3 remain developmental approaches: preclinical results are promising, but clinical antitumor activity of CAR-T therapy in RMS has so far been limited by antigen heterogeneity, an immunosuppressive microenvironment, and manufacturing barriers ^[130].

Test for mismatch-repair deficiency or microsatellite instability when pleomorphic RMS, a Lynch-syndrome phenotype, or another clinical-pathologic indication is present. A dMMR/MSI-high tumor may justify an immune-checkpoint inhibitor trial or, in selected circumstances, tissue-agnostic treatment; do not extrapolate this approach to unselected pediatric RMS. In a series of dMMR sarcomas, screening was specifically supported for pleomorphic RMS and for sarcomas accompanied by a personal or family history of Lynch syndrome ^[7].

Refer at first relapse or progression, not after exhaustion of standard drugs, to a pediatric or adult sarcoma center with access to cooperative-group and early-phase trials. Trial enrollment should capture initial localized versus metastatic status, time to event, relapse pattern, prior radiotherapy, FOXO1 status, metastatic burden, and prior treatment exposure, because these variables determine both expected benefit and interpretability of the trial result ^[126]. Integrate palliative care from the outset when disease is widely progressive or treatment morbidity exceeds a realistic chance of meaningful disease control; symptom relief, function, fertility, neurocognition, and family goals remain active treatment endpoints even when cure is unlikely.

Pearl: Confirm recurrence when feasible, restage every compartment, review the tumor biology again, and pursue a trial early; reserve aggressive local therapy for disease that can be controlled without disproportionate functional cost.

Assess response as a multidimensional clinical judgment rather than as a change in one scan. At each interval, document the palpable or visible primary tumor, pain, neurologic and neurovascular function, organ obstruction, regional nodes, performance status, weight, and treatment toxicity. A smaller mass may still contain viable tumor, whereas persistent enhancement or restricted diffusion may represent fibrosis, necrosis, hemorrhage, or treatment-related change. Conversely, a clinically quiet examination does not exclude residual or metastatic disease.

Use contrast-enhanced MRI of the primary and regional basin for most head and neck, extremity, trunk, pelvic, and genitourinary tumors; use CT when MRI is unsuitable or when cortical bone, calcification, or thoracic anatomy requires it. Compare the pretreatment tumor map with each study, including the original extent, biopsy tract, involved compartments, neurovascular relationships, and nodal sites. Apply RECIST 1.1 consistently for measurable disease; a pediatric cohort used revised RECIST 1.1 to classify complete response, partial response, stable disease, progressive disease, and relapse. ^[41] Re-image during systemic treatment at the protocol-defined interval and before local control, but do not change therapy solely because a lesion has stopped shrinking when there is no confirmed progression.

A radiographic complete response is not a pathologic complete response. MRI or CT can demonstrate disappearance of measurable disease without proving eradication of viable RMS; conversely, residual imaging abnormality after treatment does not prove persistent tumor. When surgery or a second-look biopsy is performed, report treatment effect and viable tumor separately, and interpret the specimen against the pretreatment map. The response category is therefore an assessment of imaging behavior, not a replacement for pathology or for the post-treatment residual-disease designation.

Obtain thin-section chest CT for pulmonary assessment, because FDG-PET can miss small lung metastases; in one pediatric series, PET/CT failed to detect a 0.6-cm pulmonary nodule seen on chest CT. ^[55] Add FDG-PET/CT or PET/MRI when nodal, osseous, or otherwise discordant metastatic disease would alter management. PET findings require anatomic correlation because uptake is not specific for viable RMS; SUVmax is not a validated predictive or prognostic biomarker in pediatric RMS. ^[55] Use symptom-directed MRI, CT, or other imaging for bone, spine, brain, or abdominal disease rather than allowing a negative PET study to substitute for an indicated examination.

Do not confuse response with formal risk classification. Pretreatment TNM, IRS group , age, primary site, tumor size, regional nodal status, distant metastases, histologic pattern, and molecular class determine risk; response may refine the local-control decision but does not retroactively convert Group III or Group IV disease into Group I disease. The IRS system defines Group I by complete resection with node-negative disease, Group II by microscopic residual disease and/or resected involved nodes, Group III by biopsy-only or gross residual disease, and Group IV by metastatic disease regardless of local resection. ^[41] A single-center retrospective study found metastatic disease to be the dominant adverse factor, with 5-year EFS and OS of 35.0% and 40.0% for metastatic disease versus 83.9% for both endpoints in localized disease; these estimates are descriptive and should not replace cooperative-group risk models. ^[41]

Determinants of outcome

Age modifies risk through biology, treatment tolerance, site distribution, and the classification system used; interpret it together with tumor site rather than in isolation. Primary site matters because orbit, nonparameningeal head and neck, and selected genitourinary sites are more favorable than parameningeal, bladder/prostate, extremity, and perineal sites. Tumor diameter greater than 5 cm, invasion of adjacent structures, and regional nodal involvement increase the probability of residual or disseminated disease, although a small tumor can still be biologically aggressive. Regional nodes deserve particular attention in extremity and alveolar tumors: in a small trunk-and-extremity cohort, relapse/progression occurred in 66.7% of node-positive patients versus 22.2% of node-negative patients, a clinically concerning but statistically imprecise difference. ^[32]

Distant metastasis at diagnosis is the strongest adverse clinical marker, particularly when bone or marrow is involved, several organ systems are affected, or the patient is younger than 1 year or at least 10 years. In the same small cohort, relapse/progression occurred in 85.7% of patients with metastases at diagnosis and in none of those with localized disease; the sample was only 15 patients, so the magnitude should not be generalized without qualification. ^[32] Record the metastatic compartments, marrow status, and response of each compartment separately rather than reducing metastatic disease to a binary label.

IRS group expresses residual disease after biopsy or surgery and therefore captures the completeness of local control. Gross residual disease is consistently more adverse than microscopic residual disease or complete resection; in a retrospective localized cohort, 5-year EFS was 100.0% after R0 resection, 96.3% after R1 resection, and 46.7% after R2 resection. ^[41] These results are subject to selection bias, because tumors that can be removed completely are often anatomically and biologically more favorable. The therapeutic objective remains durable local control with preservation of function, not radical surgery that creates avoidable disability.

Histologic pattern must be interpreted with molecular data. Fusion-positive RMS, especially PAX3::FOXO1-positive disease, generally carries greater risk than fusion-negative disease; alveolar architecture without a FOXO1 fusion is not biologically equivalent to fusion-positive alveolar RMS. MYOD1-altered spindle/sclerosing RMS and tumors with adverse TP53 biology require particular caution because morphology alone may underestimate risk. In adults and adolescents, confirm that the molecular result is technically adequate before using it for prognostic counseling; missing fusion data can misclassify risk, as occurred in a retrospective cohort in which early cases were not uniformly tested. ^[41]

Time to relapse is itself prognostic and should be recorded precisely from diagnosis, completion of planned therapy, and first documented remission. A recurrence during treatment or soon after completion usually signals more resistant disease than a late recurrence, but timing cannot be interpreted independently of the original site, metastatic status, fusion class, and pattern of relapse. At every recurrence-free visit, ask specifically about new mass, pain, cough, dyspnea, focal neurologic symptoms, bleeding, urinary symptoms, and functional decline; these symptoms determine whether surveillance imaging should be brought forward.

Surveillance after treatment

Use a written survivorship care plan that states the original diagnosis and fusion status, TNM stage, IRS group, metastatic sites, cumulative chemotherapy exposures, radiation fields and doses, operations, margins, complications, fertility preservation measures, and the schedule for imaging and laboratory review. A practical RMS surveillance pattern is clinical assessment and disease-directed imaging every 3 months for the first 2 years, every 6 months in the third year, and annually thereafter, as used in a pediatric trunk-and-extremity cohort. ^[32] Tailor the schedule to original site, risk, symptoms, and protocol; extend focused surveillance when the expected latency of treatment injury exceeds the period of relapse surveillance.

Examine the primary site and regional basin at every visit, assessing scar or radiation field, deep mass, asymmetry, range of motion, strength, sensation, distal perfusion, cranial-nerve and visual function when relevant, and organ-specific function. Use MRI for a suspicious local finding and obtain image-guided core biopsy when recurrence is plausible and tissue confirmation would change management. For pulmonary surveillance, use chest CT when clinically indicated or protocol-required, particularly in patients with pulmonary metastatic risk; a normal examination and normal chest radiograph do not exclude small lung lesions. ^[55]

Discuss second malignancy risk without creating unnecessary imaging exposure. Review prior radiation fields, constitutional cancer predisposition, family history, new persistent masses, unexplained cytopenias, and unusual skin or organ findings. In patients with constitutional TP53 alterations, minimize ionizing radiation when an equally effective non-ionizing assessment is available and coordinate surveillance with genetics and a high-risk cancer program. A new lesion in a prior radiation field is not automatically a recurrence or a second malignancy; obtain tissue whenever feasible and management-changing.

Late effects and rehabilitation

Late-effect review must be exposure-based. Alkylators warrant assessment of gonadal reserve, puberty, menstrual and sexual function, and renal tubular function; anthracyclines warrant lifelong cardiovascular history, examination, blood pressure measurement, and risk-adapted echocardiography; radiation warrants examination of the irradiated organs, growth plates, endocrine axes, dentition, cognition, and risk of a later malignancy. Surgery warrants review of wound, scar, limb or facial asymmetry, strength, range of motion, continence, sexual function, and organ-specific reconstruction. Record cumulative doses and operative anatomy so that future clinicians do not have to reconstruct risk from incomplete records.

Offer fertility and reproductive counseling before treatment and revisit it after treatment, because gonadal toxicity may emerge during puberty or when pregnancy is desired. Refer females for menstrual, ovarian-reserve, uterine, and pregnancy counseling and males for testicular function and semen or sperm-production counseling; involve reproductive endocrinology when preservation or assisted reproduction is feasible. Coordinate pregnancy planning with maternal-fetal medicine, genetics, and the sarcoma team when prior pelvic treatment, gonadal failure, cardiac exposure, or a cancer-predisposition syndrome is present.

Assess growth, puberty, thyroid and pituitary-hypothalamic function, bone health, dentition, hearing, vision, renal and bladder function, cardiac status, cognition, school or work performance, and psychosocial health. Head and neck survivors require structured ophthalmologic, audiologic, dental, facial-growth, and endocrine follow-up. In a long-term ophthalmologic cohort, mean doses above 40 GyEQD2 to the orbit, 10 GyEQD2 to the lacrimal gland, and 6 GyEQD2 to the lens were associated with more than a 20% probability of globe displacement, dry eye, or cataract; retinopathy and optic neuropathy occurred after maximum retinal and optic-nerve doses above 40 and 53 GyEQD2, respectively. ^[103] Orbital follow-up should therefore continue beyond routine early survivorship, because cataracts in one retrospective series appeared as late as 95 months after diagnosis. ^[53]

Refer early to physical and occupational therapy for weakness, contracture, lymphedema, gait disturbance, impaired fine motor function, facial asymmetry, or reduced activities. Use speech, swallowing, audiology, ophthalmology, prosthetic, continence, and pelvic-floor services according to the treated site. Obtain dental review after head and neck treatment; a validated radiographic dental tool used a threshold score of 16 points to identify patients needing specialized dental care, with 100% sensitivity and 90.0% specificity in its validation study. ^[138]

Ask directly about anxiety, depression, trauma symptoms, body image, sexual health, school reintegration, employment, health insurance, financial toxicity, family strain, and fear of recurrence. Provide psychology, social work, peer support, sexual-health care, and neuropsychology rather than waiting for a crisis. Review immunizations, influenza and COVID-19 vaccination, age-appropriate cancer screening, blood pressure, lipids, exercise, nutrition, sleep, tobacco and substance use, dental prevention, and primary care follow-up. Coordinate live vaccines with the treating team when immune recovery is incomplete, and document individualized revaccination needs after intensive therapy.

Transition to adult follow-up should be planned, not triggered by loss to follow-up. Begin education before transfer: the survivor should be able to describe the original RMS, major exposures, late-effect risks, fertility status, emergency symptoms, and the location of the treatment summary. Transfer a concise medical record directly to an adult sarcoma or survivorship clinician, confirm responsibility for surveillance imaging and cardiac, endocrine, renal, reproductive, dental, and psychosocial care, and maintain access to pediatric specialists for complex late effects. Adolescents and young adults remain underserved; collaboration between pediatric and adult practices is recommended to improve continuity and trial access. ^[6]